Rationale for current therapies in Parkinson’s disease

Author： Romrell Janet Fernandez Hubert H Okun Michael S

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.4, Iss.10, 2003-10, pp. : 1747-1761

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging Therapies in the Pharmacological Treatment of Parkinsons Disease

By Korczyn A.D. Nussbaum M.

Drugs, Vol. 62, Iss. 5, 2002-01 ,pp. : 775-786

Adis International

Access to resources Recommend Favorite

Existing dopaminergic therapies for Parkinson’s disease

By Dutta PhD Aloke K Le MD PhD Weidong

Expert Opinion on Therapeutic Patents, Vol. 16, Iss. 12, 2006-12 ,pp. : 1613-1625

Informa Healthcare

Access to resources Recommend Favorite

Gene Therapy in Parkinson's Disease: Rationale and Current Status

By > Maguire-Zeiss Kathleen A.

CNS Drugs, Vol. 24, Iss. 3, 2010-03 ,pp. : 177-192

Adis International

Access to resources Recommend Favorite

Adenosine A2A Receptor Antagonists for Parkinsons Disease: Rationale, Therapeutic Potential and Clinical Experience

By Hauser Robert A.

Drugs & Aging, Vol. 22, Iss. 6, 2005-01 ,pp. : 471-482

Adis International

Access to resources Recommend Favorite

Alzheimer’s Disease and Parkinson’s Disease: A Review of Current Treatment Adopting a Nanotechnology Approach

Current Pharmaceutical Design, Vol. 24, Iss. 1, 2018-03 ,pp. : 22-45

Bentham Science Publishers

Access to resources Recommend Favorite